PharmaCyte Biotech Inc
For the period ended Apr 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Aug 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
None.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| PharmaCyte Biotech, Inc. | |
| August 13, 2024 | By: /s/ Joshua N. Silverman |
|---|---|
| Joshua N. Silverman Interim Chief Executive Officer | |
| (Duly Authorized Officer and Principal Executive Officer) | |
| August 13, 2024 | By: /s/ Carlos A Trujillo Carlos A. Trujillo Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer) |
Pursuant to the requirements of the Exchange Act, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| August 13, 2024 | By: /s/ Joshua N. Silverman Joshua N. Silverman Interim Chief Executive Officer, Interim Chairman of the Board and Director (Principal Executive Officer) |
|---|---|
| August 13, 2024 | By: /s/ Carlos A. Trujillo Carlos A. Trujillo Chief Financial Officer and Director (Principal Financial and Accounting Officer) |
| August 13, 2024 | By: /s/ Jonathan L. Schechter Jonathan L. Schechter, Director |
| August 13, 2024 | By: /s/ Robert Weinstein Robert Weinstein, Director |
| August 13, 2024 | By: /s/ Michael M. Abecassis |
| Michael M. Abecassis, Director | |
| August 13, 2024 | By: /s/ Wayne R. Walker |
| Wayne R. Walker, Director |
SUPPLEMENTAL INFORMATION TO BE FURNISHED WITH REPORTS
FILED PURSUANT TO SECTION 15(d) OF THE ACT BY REGISTRANTS WHICH HAVE NOT REGISTERED SECURITIES PURSUANT TO SECTION 12 OF THE ACT
The registrant has not sent to its security holders any annual report covering the registrant’s fiscal year ended April 30, 2024.
CONTENTS
| Report of Independent Registered Public Accounting Firm - Marcum (PCAOB Auditor ID: 688) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm - Armanino (PCAOB Auditor ID: 32) | F-4 |
| Consolidated Balance Sheets as of April 30, 2024, and 2023 | F-5 |
| Consolidated Statements of Operations for the Years Ended April 30, 2024, and 2023 | F-6 |
| Consolidated Statements of Comprehensive Income (Loss) for the Years Ended April 30, 2024, and 2023 | F-7 |
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity for the Years Ended April 30, 2024, and 2023 | F-8 |
| Consolidated Statements of Cash Flows for the Years Ended April 30, 2024, and 2023 | F-9 |
| Notes to Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.